---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-031990"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T07:22:47.335018+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allurion raises ~$6.1M via registered direct offering and private placement to fund GLP-1 clinical pipeline

## Summary
- Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).
- Also issued 267,686 shares and 535,372 warrants to Leavitt Equity Partners at $5.23/share in a concurrent private placement.
- Total gross proceeds expected to be ~$6.1M; net proceeds will fund muscle mass/GLP-1 adherence trials, working capital, and general corporate purposes.
- As consideration, company will seek stockholder approval to reduce exercise price of Leavitt’s July 2024 warrants from $30.00 to $6.00 per share.
- Offering closed on February 20, 2025; Roth Capital Partners acted as exclusive placement agent.

## SEC filing metadata
- accession: 0001193125-25-031990
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000119312525031990/0001193125-25-031990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000119312525031990/d924898d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-031990
- JSON: https://secwatch.observer/filing/0001193125-25-031990.json
- Plain text: https://secwatch.observer/filing/0001193125-25-031990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.